
MEBO Research
It is our goal to attempt to set up 2 conference calls throughout the whole of the conference, one using the local US conference phone line utilized for the bi-weekly calls, and the other a Skype Voice call. I cannot guarantee that the Skype call will be possible, but if you open an account to make domestic and international Skype calls in advance, you can purchase credits and take advantage of their very low long distance rates (usually cents per minute), and you can call the US conference phone line and listen in. More details and instructions will be posted in this blog tomorrow, the day before the conference.

access code : 391629#
NON USA : add 001 prefix
CONFERENCE AGENDA
The following is the agenda of the Conference to be held this Saturday, June 23rd at 12:00 noon and will last approximately 4 hours. The following days and weeks after the meetup, each presentation will be posted in this blog for everyone to see.
- PowerPoint Presentation by
Elizabeth Shephard, PhD
Professor of Molecular Biology
Vice Dean Education, Biosciences
Institute of Structural and Molecular Biology
Division of Biosciences
Darwin Building, UCL Genetics Institute
University College London
MEBO Research Scientific Advisor
Member of the MEBO Institutional Review Board - Drug metabolism: If you have a mutation in a drug metabolizing enzyme that is needed to clear a particular drug, then there is very little detoxification and change in the drug, and the plasma concentration remains high. When taking the next dose, the same happens, thus the plasma concentration will increase over time without decreasing between each dose. This is potential for adverse effects, “adverse drug effects,” and in worst-case scenario, having too much drug, overdosing, and even death.
- PHARMACOGENETICS (A field of genetics)--> PERSONALIZED MEDICINE:
Pharmacogentics: The study of how our genes influence the way we handle a drug. Personalized medicine is, if we understand a person’s genetics, can we tailor their drug treatment to get them the best response to their particular drugs.
Dr. Shephard gives an extensive list in her PowerPoint presentation of modern day medications that significantly challenge some metabolic pathways. - PowerPoint Presentation by
Dr. Colin Harvey-Woodworth, BDS
UK MEBO Research Scientific Director
Member of the MEBO Institutional Review Board - Dimethylsulfide (DMS) appears to be a substrate of both CYP and FMO; renal and pulmonary excretion; DMS also demonstrated in cow milk after the cow’s dietary loading with either DMS or methionine
- DMS is a component of the odor of feces and flatus, along with H2S and methyl mercaptan
(the same 3 VSC implicated as being the greatest contributors to the various forms of halitosis) - these VSCs likely the result of intestinal bacterial activity
- of all the VSC gasses produced in the colon, >90% are absorbed by the gut lining rather than being emitted as flatus
- insufficiency of normal methionine pathway likely result in dimethylsulfidemia in addition to hypermethioninemia
Dimethylsufidemia: its significance in extra-oral blood borne halitosis: